Custom service
High Concentration Formulation (HCF) Technology
Getting a protein to 100 mg/mL and still monomeric.
High-concentration formulation is a physico-chemical problem dressed as a processing task. Concentrating by ultrafiltration is easy; keeping the protein monomeric, pourable and stable at 100–200 mg/mL is not. Viscosity rises steeply, opalescence signals reversible self-association, and aggregation that was negligible at 5 mg/mL becomes the dominant degradation pathway at 150.
The formulation screen precedes the concentration. Excipients — arginine and its salts to disrupt self-association, polysorbate to protect interfaces, histidine and other buffers at the pH that minimises charge-driven association, sodium chloride tuned to the protein's colloidal behaviour — are screened at intermediate concentration by DLS, viscosity and accelerated stability. The winning buffer is the one that keeps monomer content high and viscosity manageable at the target concentration.
Concentration is then run with process awareness: tangential flow filtration with pressure and flux controlled to avoid shear-driven aggregation, temperature held low, hold times minimised. The final formulation is characterised at full concentration — monomer by SEC, viscosity by rheometry, opalescence, and accelerated stability at the intended storage temperature — because a formulation validated only at low concentration predicts nothing about behaviour at 150.
HCF is needed for subcutaneous injection volumes, for reagent stocks where storage volume matters, and for any product whose concentration requirement exceeds what standard buffers will support.
It is not applicable when the protein's colloidal behaviour cannot be managed by excipients — some proteins self-associate irreversibly at any useful concentration — and the feasibility assessment identifies those early.
Each lot is released with concentration by A280 and gravimetric check, SEC-HPLC monomer content at full concentration, viscosity, opalescence, endotoxin where relevant, and the accelerated stability data from the initial storage period. The formulation composition is documented in full.
Service Highlights
- Excipient screen first. Arginine, polysorbate, buffer species, pH and salt screened for their effect on self-association before concentration is attempted.
- Colloidal behaviour measured. DLS and diffusion interaction parameters quantify self-association, so buffer choice is data-driven.
- Viscosity managed. Rheometry at target concentration, with viscosity-reducing excipients evaluated where pourability matters.
- Shear-aware concentration. TFF pressure and flux controlled, with hold times and temperatures specified.
- Accelerated stability. Monomer content tracked at intended and elevated temperatures over the initial storage period.
- Full-concentration QC. SEC, viscosity, opalescence and concentration verified at the final protein level, not extrapolated from dilute samples.
How the work runs
Feasibility assessment
Current behaviour at intermediate concentration — aggregation, viscosity, opalescence — characterised to size the problem.
Excipient screen
Buffer species, pH, salt and excipients screened by DLS, viscosity and stability at intermediate concentration.
Concentration development
TFF conditions developed with pressure, flux and temperature controlled.
Concentration to target
Protein concentrated under the developed conditions to the target level.
Full-concentration characterisation
Monomer content, viscosity, opalescence and concentration measured at the final level.
Stability and release
Accelerated stability run, formulation documented, and lot released with the complete dataset.
Specifications & timeline
- Concentration range
- 50–200 mg/mL, target-dependent
- Formats
- Liquid formulation in defined buffers; lyophilised alternatives available
- Methods
- TFF, excipient screening, DLS, rheometry, SEC, accelerated stability
- Scale
- 50 mg to 10 g per batch
- Timeline
- 3–6 weeks per formulation
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.